APO Research
Talk to an analyst

APO RESEARCH · REPORT

ESR1 Mutated Metastatic Breast Cancer Diagnostics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Outlook and Growth Opportunities 2026

2 May 2026183 pages

Choose your research edition.

Industry ResearchESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal ESR1 Mutated Metastatic Breast Cancer Diagnostics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Outlook and Growth Opportunities 2026183 pages · $4,250 USDMarket Analysis & ForecastGlobal ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Analysis and Forecast 2026-2032252 pages · $4,950 USD

Market perspective

The global ESR1 Mutated Metastatic Breast Cancer Diagnostics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the ESR1 Mutated Metastatic Breast Cancer Diagnostics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the ESR1 Mutated Metastatic Breast Cancer Diagnostics market include APIS Assay Technologies, lllumina, Inc., GENCURIX, RainSure Scientific, NeoGenomics Laboratories, Sysmex Corporation, ASURAGEN,INC and Guardant Health, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of ESR1 Mutated Metastatic Breast Cancer Diagnostics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents ESR1 Mutated Metastatic Breast Cancer Diagnostics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market.

ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Company

APIS Assay Technologies

lllumina, Inc.

GENCURIX

RainSure Scientific

NeoGenomics Laboratories

Sysmex Corporation

ASURAGEN,INC

Guardant Health

ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Type

NGS Based

PCR Based

ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Application

Hospital Associated Labs

lndependent Diagnostic Laboratories

Diagnostic Imaging Centers

Cancer Research lnstitutes

ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global ESR1 Mutated Metastatic Breast Cancer Diagnostics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the ESR1 Mutated Metastatic Breast Cancer Diagnostics key companies, revenue, market share, and recent developments.

3. To split the ESR1 Mutated Metastatic Breast Cancer Diagnostics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions ESR1 Mutated Metastatic Breast Cancer Diagnostics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify ESR1 Mutated Metastatic Breast Cancer Diagnostics significant trends, drivers, influence factors in global and regions.

6. To analyze ESR1 Mutated Metastatic Breast Cancer Diagnostics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of ESR1 Mutated Metastatic Breast Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ESR1 Mutated Metastatic Breast Cancer Diagnostics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global ESR1 Mutated Metastatic Breast Cancer Diagnostics industry.

Chapter 3: Detailed analysis of ESR1 Mutated Metastatic Breast Cancer Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of ESR1 Mutated Metastatic Breast Cancer Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of ESR1 Mutated Metastatic Breast Cancer Diagnostics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Trends Table 2. ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Drivers Table 3. ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Opportunities and Challenges Table 4. ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Restraints Table 5. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Company (2021-2026) Table 7. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Company Manufacturing Base & Headquarters Table 9. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Company, Product Type & Application Table 10. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of NGS Based Table 15. Significant Companies of PCR Based Table 16. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type (2021-2026) Table 20. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Associated Labs Table 22. Significant Companies of lndependent Diagnostic Laboratories Table 23. Significant Companies of Diagnostic Imaging Centers Table 24. Significant Companies of Cancer Research lnstitutes Table 25. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application (2021-2026) Table 29. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application (2027-2032) Table 30. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Region (2021-2026) Table 33. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Region (2027-2032) Table 35. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Market Share by Country (2021-2026) Table 38. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Market Share by Country (2027-2032) Table 40. APIS Assay Technologies Company Information Table 41. APIS Assay Technologies Business Overview Table 42. APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 44. APIS Assay Technologies Recent Development Table 45. lllumina, Inc. Company Information Table 46. lllumina, Inc. Business Overview Table 47. lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 49. lllumina, Inc. Recent Development Table 50. GENCURIX Company Information Table 51. GENCURIX Business Overview Table 52. GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 54. GENCURIX Recent Development Table 55. RainSure Scientific Company Information Table 56. RainSure Scientific Business Overview Table 57. RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 59. RainSure Scientific Recent Development Table 60. NeoGenomics Laboratories Company Information Table 61. NeoGenomics Laboratories Business Overview Table 62. NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 64. NeoGenomics Laboratories Recent Development Table 65. Sysmex Corporation Company Information Table 66. Sysmex Corporation Business Overview Table 67. Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 69. Sysmex Corporation Recent Development Table 70. ASURAGEN,INC Company Information Table 71. ASURAGEN,INC Business Overview Table 72. ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 74. ASURAGEN,INC Recent Development Table 75. Guardant Health Company Information Table 76. Guardant Health Business Overview Table 77. Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 79. Guardant Health Recent Development Table 80. Research Programs/Design for This Report Table 81. Authors List of This Report Table 82. Secondary Sources Table 83. Primary Sources List of Figures Figure 1. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Image Figure 2. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2021-2032) & (US$ Million) Figure 4. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. NGS Based Image Figure 8. PCR Based Image Figure 9. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type (2021-2032) Figure 12. Hospital Associated Labs Image Figure 13. lndependent Diagnostic Laboratories Image Figure 14. Diagnostic Imaging Centers Image Figure 15. Cancer Research lnstitutes Image Figure 16. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application (2021-2032) Figure 19. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 22. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 24. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 28. South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • NGS Based
  • PCR Based
Applications
  • Hospital Associated Labs
  • lndependent Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Cancer Research lnstitutes
Companies covered
  • APIS Assay Technologies
  • lllumina, Inc.
  • GENCURIX
  • RainSure Scientific
  • NeoGenomics Laboratories
  • Sysmex Corporation
  • ASURAGEN,INC
  • Guardant Health

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Dynamics
  1. 2.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Trends
  2. 2.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Drivers
  3. 2.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Opportunities and Challenges
  4. 2.4 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Restraints
3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market by Company
  1. 3.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Company Revenue Ranking in 2025
  2. 3.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Company (2021-2026)
  3. 3.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Company Ranking (2024-2026)
  4. 3.4 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Company Manufacturing Base and Headquarters
  5. 3.5 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Company Product Type and Application
  6. 3.6 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 ESR1 Mutated Metastatic Breast Cancer Diagnostics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market by Type
  1. 4.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Type Introduction
  2. 4.1.1 NGS Based
  3. 4.1.2 PCR Based
  4. 4.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Type
  5. 4.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Type (2021-2032)
  7. 4.2.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type (2021-2032)
5 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market by Application
  1. 5.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Application Introduction
  2. 5.1.1 Hospital Associated Labs
  3. 5.1.2 lndependent Diagnostic Laboratories
  4. 5.1.3 Diagnostic Imaging Centers
  5. 5.1.4 Cancer Research lnstitutes
  6. 5.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Application
  7. 5.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Application (2021-2032)
  9. 5.2.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application (2021-2032)
6 ESR1 Mutated Metastatic Breast Cancer Diagnostics Regional Value Analysis
  1. 6.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Region (2021-2032)
  3. 6.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Region: 2021-2026
  4. 6.2.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value (2021-2032)
  7. 6.3.2 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value (2021-2032)
  10. 6.4.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value (2021-2032)
  16. 6.6.2 South America ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
7 ESR1 Mutated Metastatic Breast Cancer Diagnostics Country-level Value Analysis
  1. 7.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Country (2021-2032)
  3. 7.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Country (2021-2026)
  4. 7.2.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 APIS Assay Technologies
  2. 8.1.1 APIS Assay Technologies Company Information
  3. 8.1.2 APIS Assay Technologies Business Overview
  4. 8.1.3 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  6. 8.1.5 APIS Assay Technologies Recent Developments
  7. 8.2 lllumina, Inc.
  8. 8.2.1 lllumina, Inc. Company Information
  9. 8.2.2 lllumina, Inc. Business Overview
  10. 8.2.3 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  12. 8.2.5 lllumina, Inc. Recent Developments
  13. 8.3 GENCURIX
  14. 8.3.1 GENCURIX Company Information
  15. 8.3.2 GENCURIX Business Overview
  16. 8.3.3 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  18. 8.3.5 GENCURIX Recent Developments
  19. 8.4 RainSure Scientific
  20. 8.4.1 RainSure Scientific Company Information
  21. 8.4.2 RainSure Scientific Business Overview
  22. 8.4.3 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  24. 8.4.5 RainSure Scientific Recent Developments
  25. 8.5 NeoGenomics Laboratories
  26. 8.5.1 NeoGenomics Laboratories Company Information
  27. 8.5.2 NeoGenomics Laboratories Business Overview
  28. 8.5.3 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  30. 8.5.5 NeoGenomics Laboratories Recent Developments
  31. 8.6 Sysmex Corporation
  32. 8.6.1 Sysmex Corporation Company Information
  33. 8.6.2 Sysmex Corporation Business Overview
  34. 8.6.3 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  36. 8.6.5 Sysmex Corporation Recent Developments
  37. 8.7 ASURAGEN,INC
  38. 8.7.1 ASURAGEN,INC Company Information
  39. 8.7.2 ASURAGEN,INC Business Overview
  40. 8.7.3 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  42. 8.7.5 ASURAGEN,INC Recent Developments
  43. 8.8 Guardant Health
  44. 8.8.1 Guardant Health Company Information
  45. 8.8.2 Guardant Health Business Overview
  46. 8.8.3 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  48. 8.8.5 Guardant Health Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst